Double et triple agonistes : rôle du glucagon

Scheen, André

doi:10.1016/j.mmm.2023.06.006

Request a copy

Article (Scientific journals)

Double et triple agonistes : rôle du glucagon

Scheen, André

2023 • In Médecine des Maladies Métaboliques, 17 (5), p. 399-405

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/306110

DOI
10.1016/j.mmm.2023.06.006

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2023 MMM role du glucagon double et triple agonists.pdf

Author postprint (566.75 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Agoniste double GIP/GLP-1; Diabète de type 2; Glucagon; Glucagon-like peptide-1; Glucose-dependent; insulinotropic polypeptide; Insuline; Tirzépatide

Abstract :

[fr] Le glucagon, la « seconde hormone pancréatique », joue un rôle important dans l'homéostasie glycémique et la régulation énergétique. Le glucagon-like peptide-1 (GLP-1) inhibe sa sécrétion et cet effet participe à l'amélioration du contrôle glycémique obtenu avec les agonistes des récep- teurs du GLP-1 chez les patients avec diabète de type 2 (DT2). Les effets du « glucose-dependent insulinotropic polypeptide » (GIP), une autre hormone intestinale à action incrétine, sur la sécrétion du glucagon apparaissent plus équivoques, influencés par le niveau de glycémie et les caractéristiques de l'individu (sujet sain versus personne DT2). Un agoniste unimoléculaire biaisé à action double GIP/GLP-1, le tirzépatide, est maintenant disponible pour le traitement du DT2. Le but de cet article est d'analyser les effets du GLP-1, du GIP et du tirzépatide sur la sécrétion du glucagon et le rôle éventuel de cette modulation du glucagon par cette molécule originale sur l'homéostasie glycémique du patient avec un DT2. Des agonistes triples, GIP/GLP-1/glucagon sont en cours de développement dans l'espoir de stimuler le métabolisme énergétique et de promouvoir davantage la perte pondérale chez les patients obèses avec ou sans DT2.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques

Language :

French

Title :

Double et triple agonistes : rôle du glucagon

Alternative titles :

[en] Dual and triple agonists: Role of glucagon

Publication date :

2023

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Volume :

Issue :

Pages :

399-405

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164697088&doi=10.1016%2fj.mmm.2023.06.006&partnerID=40&md5=f0208c1e7c3faabe00717029506cd276

Commentary :

cited By 1
Scopus

Available on ORBi :

since 31 August 2023

Statistics

Number of views

17 (2 by ULiège)

Number of downloads

1 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Scheen, A.J., Lefèbvre, P.J., Glucagon, from past to present: a century of intensive research and controversies. Lancet Diabetes Endocrinol 11 (2023), 129–138.
Cryer, P.E., Gerich, J.E., Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus. N Engl J Med 313 (1985), 232–241.
Cryer, P.E., Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 153 (2012), 1039–1048.
Unger, R.H., Cherrington, A.D., Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 122 (2012), 4–12.
Lefèbvre, P.J., Paquot, N., Scheen, A.J., Inhibiting or antagonizing glucagon: making progress in diabetes care. Diabetes Obes Metab 17 (2015), 720–725.
Scheen, A.J., Paquot, N., Lefèbvre, P.J., Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes. Expert Opin Investig Drugs 26 (2017), 1373–1389.
Lefèbvre, P., Glucagon’ s golden jubilee at the University of Liège. Br J Diabetes Vasc Dis 12 (2012), 278–284.
Müller, T.D., Finan, B., Clemmensen, C., et al. The new biology and pharmacology of glucagon. Physiol Rev 97 (2017), 721–766.
Haedersdal, S., Andersen, A., Knop, F.K., Vilsbøll, T., Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases. Nat Rev Endocrinol 19 (2023), 321–335.
Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
Scheen, A.J., Clinical pharmacology of antidiabetic drugs: what can be expected of their use?. Presse Med, 52, 2022, 104158.
Davies, M.J., Aroda, V.R., Collins, B.S., et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65 (2022), 1925–1966.
Scheen, A.J., Radermecker, R.P., Paquot, N., Focus sur le tirzépatide, un double agoniste unimoléculaire GIP-GLP-1 dans le diabète de type 2. Rev Med Suisse 18 (2022), 1539–1544.
Scheen, A.J., Dual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes. Ann Endocrinol (Paris) 84 (2023), 316–321.
Nauck, M.A., Kleine, N., Orskov, C., et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36 (1993), 741–744.
Hare, K.J., Vilsbøll, T., Asmar, M., et al. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 59 (2010), 1765–1770.
Mentis, N., Vardarli, I., Köthe, L.D., et al. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 60 (2011), 1270–1276.
Christensen, M.B., Calanna, S., Holst, J.J., et al. Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. J Clin Endocrinol Metab 99 (2014), E418–E426.
Lund, A., Vilsbøll, T., Bagger, J.I., et al. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab 300 (2011), E1038–E1046.
Heise, T., Mari, A., DeVries, J.H., et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol 10 (2022), 418–429.
Christensen, M., Vedtofte, L., Holst, J.J., et al. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60 (2011), 3103–3109.
El, K., Campbell, J.E., The role of GIP in α-cells and glucagon secretion. Peptides, 125, 2020, 170213.
Mathiesen, D.S., Bagger, J.I., Bergmann, N.C., et al. The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A review. Int J Mol Sci, 20, 2019, 4092.
Willard, F.S., Douros, J.D., Gabe, M.B., et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5, 2020, e140532.
Kaneko, S., Tirzepatide: a novel, once-weekly dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes. touchREV Endocrinol., 18, 2022, 10–19.
Zhao, F., Zhou, Q., Cong, Z., et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP. GLP-1 or glucagon receptors. Nat Commun, 13, 2022, 1057.
Frias, J.P., Nauck, M.A., Van, J., et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392 (2018), 2180–2193.
Schmitt, C., Portron, A., Jadidi, S., et al. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus. Diabetes Obes Metab 19 (2017), 1436–1445.
Caruso, I., Marrano, N., Biondi, G., et al. Glucagon in type 2 diabetes: friend or foe?. Diabetes Metab Res Rev, 39, 2023, e3609.
Scheen, A.J., Paquot, N., Obesity. A new paradigm for treating obesity and diabetes mellitus. Nat Rev Endocrinol 11 (2015), 196–198.
Müller, T.D., Tschöp, M.H., Gut-hormone triple agonists: clinical safety and metabolic benefits. Lancet 400 (2022), 1826–1828.
Bossart, M., Wagner, M., Elvert, R., et al. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. Cell Metab 34 (2022), 59–74.e10.
Urva, S., Coskun, T., Loh, M.T., et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet 400 (2022), 1869–1881.